Avidity acquisition news reveals the latest Phase 3 setback for Novartis’ dystrophy drug, raising concerns in the pharma industry.
Recent Posts
- Vamorolone South Korea approval: A Smart Move for Nxera
- Citi Pharma acquisition news: Proven benefits of CCP approval
- Export NOC for r-DNA drugs: Is it the Best Move?
- Compassionate Personal Care Assistance Elmhurst for Greater Comfort and Independence
- Are Drug Price Caps the Best Solution for Life-Saving Medicines?



